Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleoproteins are complexes of nucleic acids (DNA or RNA) with proteins, primarily located within the cell nucleus. In the context of Systemic Lupus Erythematosus (SLE), nucleoproteins serve as major autoantigens. Autoantibodies against nucleoproteins form immune complexes, contributing to inflammation and tissue damage. Therapeutic strategies aim to suppress the autoimmune response against these complexes, often by targeting B cells, T cells, or inflammatory cytokines like type I interferon.
Varies depending on the therapeutic agent. Examples include B-cell depletion, inhibition of interferon signaling, and suppression of immune cell activity.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleoprotein (None).